+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Tybost"

US HIV Infection Drug Market, Dosage, Price, Sales Insight 2021 - 2026 - Product Thumbnail Image

US HIV Infection Drug Market, Dosage, Price, Sales Insight 2021 - 2026

  • Report
  • February 2021
  • 360 Pages
  • United States
From
Prezista (darunavir; Johnson & Johnson) Drug Overview 2019 - Product Thumbnail Image

Prezista (darunavir; Johnson & Johnson) Drug Overview 2019

  • Report
  • June 2019
  • 21 Pages
  • Global
Stribild Drug Overview 2019 - Product Thumbnail Image

Stribild Drug Overview 2019

  • Report
  • June 2019
  • 16 Pages
  • Global
  • 6 Results (Page 1 of 1)
Loading Indicator

Tybost is a drug used to treat HIV and hepatitis C infections. It is a once-daily, single-tablet regimen that combines two antiretroviral drugs, cobicistat and elvitegravir. Tybost is used in combination with other antiretroviral drugs to treat HIV-1 infection in adults and adolescents aged 12 years and older. It is also used in combination with other antiviral drugs to treat chronic hepatitis C virus (HCV) infection in adults. Tybost is part of a growing market of infectious diseases drugs, which are used to treat a variety of illnesses caused by viruses, bacteria, fungi, and parasites. These drugs are used to treat a range of conditions, from common colds to more serious illnesses such as HIV and hepatitis C. The market for infectious diseases drugs is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include Gilead Sciences, Merck & Co., Johnson & Johnson, Pfizer, and GlaxoSmithKline. Other companies in the market include Bristol-Myers Squibb, AbbVie, and Novartis. Show Less Read more